1) Strong Financial Performance and Guidance - Adjusted earnings per share (EPS) for Q1 2026 were $2.65, exceeding guidance by $0.07. - Total net revenues reached $15 billion, reflecting a 12.4% year-over-year growth and beating expectations by $300 million. - Full-year adjusted EPS guidance raised to between $14.08 and $14.28, indicating confidence in continued strong performance.

2) Immunology and Neuroscience Segment Highlights - Immunology revenues totaled $7.3 billion, with Skyrizi sales at $4.5 billion (up 29.2% YoY) and Rinvoq at $2.1 billion (up 20.2% YoY). - Skyrizi is gaining significant market share in psoriatic disease and IBD, supported by strong clinical data and FDA label expansions. - Neuroscience revenues were nearly $2.9 billion, with Vraylar sales at $905 million (up 18.4%) and continued growth in migraine treatments.

3) Pipeline Advancements and R&D Investments - Progress in R&D includes regulatory submissions for Rinvoq in alopecia areata and Skyrizi's subcutaneous induction in Crohn's disease, with approvals expected later this year. - Significant investments in manufacturing, including a $1.4 billion campus in North Carolina, to support future growth in immunology and neuroscience. - Ongoing development of innovative therapies, such as ABBV-295 for obesity, showing promising early results.

4) Competitive Landscape and Market Dynamics - Skyrizi and Rinvoq are positioned to maintain leadership despite emerging competition, with strong clinical data supporting their efficacy. - The aesthetics segment is facing economic headwinds, with Botox and Juvederm showing modest growth; however, long-term prospects remain positive. - AbbVie is actively pursuing business development opportunities to enhance its pipeline and competitive position in key therapeutic areas.

5) Outlook and Strategic Focus - AbbVie is focused on sustaining growth through innovation and strategic investments, with a strong pipeline expected to drive future revenue. - The company remains open to acquisitions to bolster its portfolio, particularly in neuroscience and oncology. - The call did not provide specific updates on potential biosimilar settlements for Skyrizi or Rinvoq, which could impact future revenue.

Bottom line: AbbVie is demonstrating robust financial performance and strategic growth across its portfolio, particularly in immunology and neuroscience, while actively advancing its pipeline and addressing competitive pressures. The company's strong outlook and commitment to innovation position it well for long-term shareholder value.